Skip to content

Is it time to buy this market-beaten growth stock?

Why this stock could be the surprise millionaire maker of the year!
Ivan Zhelev

Investing is a complex game, but the aim is simple: Profit. Despite there being numerous avenues through which this objective can be achieved, many concentrate on short-term price movement and growth.

For those adopting a more patient strategy, certain stocks seem to offer potential for consistent long-term returns.

As Warren Buffett famously said: “If you aren’t willing to own a stock for 10 years, don’t even think about owning it for 10 minutes.” CVS Health (NASDAQ: CVS) might be one such stock, offering potential long-term value.


CVS strong fundamentals

CVS, often perceived as a stable and unexciting stock, is undergoing a transformation that could position it as a healthcare giant with substantial growth potential. 

The company has extended its reach into pharmacy benefits management and health insurance through strategic acquisitions, such as Signify Health (NYSE: SGFY) and Oak Street Health (NASDAQ: OSH). 

These acquisitions indicate CVS’s deliberate efforts to diversify its services and establish a more comprehensive presence in the healthcare industry.

However, these acquisitions could initially impact stock prices due to investment uncertainty, and the recent $10.6 billion investment in Oak Street Health and $8 billion in Signify Health could have played a role in the decline of the stock price.

CVS’s stock is presently trading just above the $64 support level, and it boasts an annual dividend yield of 3.65%.  

CVS year to date stock performance. Source: Finbold

Despite being within its 52-week low, the company released a robust Q3 earning report earlier this month. Given these factors, the current price may present a favorable opportunity to consider buying the stock. 

Analysts prediction 

The aging US population, which will drive increased healthcare, offers the potential for stronger CVS future performance.

If it can achieve an average total return of 13% over the next 25 years, it has the potential to make investors wealthy. This projection suggests that an investment of around $48,000, with the assumed growth rate and a 25-year holding period, could potentially reach $1 million. While there are no guarantees in the world of investing, CVS holds promise as a potential path to wealth creation.

Projections from 15 analysts on TipRanks over the previous quarter indicate a 12-month average price target of $87.20 for CVS.

This suggests a potential upside of almost 26% from its current price $69.32, leading to an overarching ‘Strong Buy’ recommendation. Based on the last three months’ rating, CVS has received 12 ‘Buy’ ratings, 3 ‘Hold’ ratings, and notably 0 ‘Sell’ ratings.

CVS Wall Street analyst 12-month prediction. Source: TipRanks

The highest price target for the stock is $102, meanwhile, the lowest price target is $76, still above the current price of almost $70. 

CVS faces challenges such as the health benefits segment seeing the biggest year-over-year decline in earnings, with its operating income falling by 20% to $1.5 billion. 

Also a drop in COVID-related vaccinations and testing, resulting in adjusted operating income from its pharmacy and consumer wellness segment declined by 17% to just over $1.4 billion. 

Nevertheless, the potential for recovery and growth remains a point of interest for investors.

Buy stocks now with Interactive Brokers – the most advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Services

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.